In the past decades, ubiquitously expressed enzyme, AR, which converts excess glucose to sorbitol, has been considered to be implicated in the etiology of secondary complications of diabetes such as diabetic neuropathy (DN), thus the inhibition of AR by epalrestat was used against DN clinically. Here, AR is linked to diabetic neuropathy.